Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Item TypeItem Type
-
SubjectSubject
-
YearFrom:-To:
-
More FiltersMore FiltersSourceLanguage
Done
Filters
Reset
4
result(s) for
"Talles, Frederico"
Sort by:
A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area
by
Kennedy, Jessie K.
,
Correa-Oliveira, Rodrigo
,
Hoeweler, Lara
in
Adjuvants, Immunologic
,
Adults
,
Adverse events
2023
Recombinant Schistosoma mansoni Tetraspanin-2 formulated on Alhydrogel (Sm-TSP-2/Alhydrogel) is being developed to prevent intestinal and hepatic disease caused by S. mansoni. The tegumentary Sm-TSP-2 antigen was selected based on its unique recognition by cytophilic antibodies in putatively immune individuals living in areas of ongoing S. mansoni transmission in Brazil, and preclinical studies in which vaccination with Sm-TSP-2 protected mice following infection challenge.
A randomized, observer-blind, controlled, Phase 1b clinical trial was conducted in 60 healthy adults living in a region of Brazil with ongoing S. mansoni transmission. In each cohort of 20 participants, 16 were randomized to receive one of two formulations of Sm-TSP-2 vaccine (adjuvanted with Alhydrogel only, or with Alhydrogel plus the Toll-like receptor-4 agonist, AP 10-701), and 4 to receive Euvax B hepatitis B vaccine. Successively higher doses of antigen (10 μg, 30 μg, and 100 μg) were administered in a dose-escalation fashion, with progression to the next dose cohort being dependent upon evaluation of 7-day safety data after all participants in the preceding cohort had received their first dose of vaccine. Each participant received 3 intramuscular injections of study product at intervals of 2 months and was followed for 12 months after the third vaccination. IgG and IgG subclass antibody responses to Sm-TSP-2 were measured by qualified indirect ELISAs at pre- and post-vaccination time points through the final study visit.
Sm-TSP-2/Alhydrogel administered with or without AP 10-701 was well-tolerated in this population. The most common solicited adverse events were mild injection site tenderness and pain, and mild headache. No vaccine-related serious adverse events or adverse events of special interest were observed. Groups administered Sm-TSP-2/Alhydrogel with AP 10-701 had higher post-vaccination levels of antigen-specific IgG antibody. A significant dose-response relationship was seen in those administered Sm-TSP-2/Alhydrogel with AP 10-701. Peak anti-Sm-TSP-2 IgG levels were observed approximately 2 weeks following the third dose, regardless of Sm-TSP-2 formulation. IgG levels fell to low levels by Day 478 in all groups except the 100 μg with AP 10-701 group, in which 57% of subjects (4 of 7) still had IgG levels that were ≥4-fold higher than baseline. IgG subclass levels mirrored those of total IgG, with IgG1 being the predominant subclass response.
Vaccination of adults with Sm-TSP-2/Alhydrogel in an area of ongoing S. mansoni transmission was safe, minimally reactogenic, and elicited significant IgG and IgG subclass responses against the vaccine antigen. These promising results have led to initiation of a Phase 2 clinical trial of this vaccine in an endemic region of Uganda.
NCT03110757.
Journal Article
Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults
by
Campbell, Doreen
,
Yakovleva, Anna
,
Correa-Oliveira, Rodrigo
in
Adjuvants, Immunologic - administration & dosage
,
Adolescent
,
Adult
2017
Necator americanus Glutathione-S-Transferase-1 (Na-GST-1) plays a role in the digestion of host hemoglobin by adult N. americanus hookworms. Vaccination of laboratory animals with recombinant Na-GST-1 is associated with significant protection from challenge infection. Recombinant Na-GST-1 was expressed in Pichia pastoris and adsorbed to aluminum hydroxide adjuvant (Alhydrogel) according to current Good Manufacturing Practice. Two Phase 1 trials were conducted in 142 healthy adult volunteers in the United States and Brazil, first in hookworm-naïve individuals and then in residents of a N. americanus endemic area in Brazil. Volunteers received one of three doses of recombinant Na-GST-1 (10, 30, or 100 μg) adjuvanted with Alhydrogel, adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl Lipid A (GLA-AF), or the hepatitis B vaccine. Vaccinations were administered via intramuscular injection on days 0, 56, and 112. Na-GST-1/Alhydrogel was well tolerated in both hookworm-naïve and hookworm-exposed adults, with the most common adverse events being mild to moderate injection site pain and tenderness, and mild headache and nausea; no vaccine-related severe or serious adverse events were observed. Antigen-specific IgG antibodies were induced in a dose-dependent fashion, with increasing levels observed after each vaccination in both trials. The addition of GLA-AF to Na-GST-1/Alhydrogel did not result in significant increases in specific IgG responses. In both the US and Brazil studies, the predominant IgG subclass induced against Na-GST-1 was IgG1, with lesser amounts of IgG3. Vaccination of both hookworm-naïve and hookworm-exposed adults with recombinant Na-GST-1 was safe, well tolerated, and resulted in significant antigen-specific IgG responses. Based on these results, this vaccine will be advanced into clinical trials in children and eventual efficacy studies.
ClinicalTrials.gov (NCT01261130 for the Brazil trial and NCT01385189 for the US trial).
Journal Article
Correction: Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults
by
Campbell, Doreen
,
Yakovleva, Anna
,
Correa-Oliveira, Rodrigo
in
Adults
,
Disease control
,
Immunogenicity
2020
[This corrects the article DOI: 10.1371/journal.pntd.0005574.].[This corrects the article DOI: 10.1371/journal.pntd.0005574.].
Journal Article
Drone-robot to install aerial marker balls for power lines
by
Trautmann, Paulo Victor
,
Souza, Frederico C.
,
de Carvalho, Talles M.
in
Aircraft
,
Artificial Intelligence
,
Automation
2024
To enhance the safety of our airspace, it is essential to implement devices along overhead power lines that effectively reduce the likelihood of collisions involving aircraft, helicopters, balloons, and other airborne objects. Aerial marker balls, which adhere to technical standards concerning their geometry and characteristics, are commonly used for aerial signaling on power transmission systems. Currently, aerial marker balls are installed by technicians either via helicopter or by utilizing ropes to perform the task manually. This process results in significant expenses and exposes the technicians to considerable risk. While robotic methods have been explored, they often present impractical challenges. Despite the advancements in various techniques, difficulties persist in this field. The primary objective of this paper is to design and develop a robotic module that can be attached to a drone, enabling the semi-automated installation of aerial marker balls. The robot model was designed using Computer Aided Design and Computer Aided Engineering software’s, with a subsequent description of the control system. After constructing the drone-robot, it was tested in a simulated environment, proving to be both efficient and cost-effective. This innovative approach improves not only the cost-effectiveness of aerial marker ball installation but also the safety of technicians involved in the process.
Journal Article